Aduro Biotech Announces First Patient Treated in Phase 2 Pancreatic Cancer Trial

BERKELEY, Calif.--(BUSINESS WIRE)--Aduro BioTech, Inc. announces the treatment of the first patient in the Phase 2 pancreatic cancer clinical trial of the sequential administration of two cancer vaccines: Aduro’s CRS-207 and GVAX Pancreas Cancer Vaccine (GVAX Pancreas). The randomized, controlled clinical trial will enroll a total of 90 patients to evaluate the overall survival as well as the safety and immune response.